| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1003814059 |
| P356 | DOI | 10.1007/S12026-009-8106-9 |
| P932 | PMC publication ID | 2891252 |
| P698 | PubMed publication ID | 19184537 |
| P5875 | ResearchGate publication ID | 23966297 |
| P2093 | author name string | Richard P Phipps | |
| Charles W Francis | |||
| Mark B Taubman | |||
| Neil Blumberg | |||
| Sherry L Spinelli | |||
| P2860 | cites work | CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells | Q24310570 |
| Platelet-mediated modulation of adaptive immunity: unique delivery of CD154 signal by platelet-derived membrane vesicles | Q24655248 | ||
| A randomized trial of washed red blood cell and platelet transfusions in adult acute leukemia [ISRCTN76536440] | Q24801336 | ||
| Release of biologically active CD154 during collection and storage of platelet concentrates prepared for transfusion | Q28221912 | ||
| Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood | Q28294906 | ||
| Immunobiology of dendritic cells | Q29547465 | ||
| Human platelets can activate peripheral blood B cells and increase production of immunoglobulins. | Q33291901 | ||
| Platelet washing to prevent recurrent febrile reactions to leucocyte-reduced transfusions | Q33337118 | ||
| Platelet-associated CD154 in immune thrombocytopenic purpura | Q33361212 | ||
| Platelet transfusions in infants with necrotizing enterocolitis do not lower mortality but may increase morbidity | Q33363972 | ||
| Platelets express functional Toll-like receptor-4. | Q33366814 | ||
| Platelet-derived or soluble CD154 induces vascularized allograft rejection independent of cell-bound CD154. | Q34391220 | ||
| The platelet CD40L/GP IIb-IIIa axis in atherothrombotic disease | Q35197406 | ||
| Soluble CD40 ligand accumulates in stored blood components, primes neutrophils through CD40, and is a potential cofactor in the development of transfusion-related acute lung injury | Q35849153 | ||
| New links between inflammation and thrombosis | Q36098709 | ||
| Platelet activation and the CD40/CD40 ligand pathway: mechanisms and implications for human disease | Q36161310 | ||
| Soluble CD40 ligand induces β 3 integrin tyrosine phosphorylation and triggers platelet activation by outside-in signaling | Q36350146 | ||
| Platelet-derived CD154 enables T-cell priming and protection against Listeria monocytogenes challenge | Q36508925 | ||
| Soluble CD40 ligand induces endothelial dysfunction in human and porcine coronary artery endothelial cells | Q36941078 | ||
| The role of platelet CD154 in the modulation in adaptive immunity | Q36961079 | ||
| Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer | Q37416199 | ||
| Expression of Toll-like receptors on human platelets | Q37866864 | ||
| Increased risk of infection and mortality in women after cardiac surgery related to allogeneic blood transfusion. | Q40432667 | ||
| Differential downstream effects of CD40 ligation mediated by membrane or soluble CD40L and agonistic Ab: a study on purified human B cells. | Q40460964 | ||
| Reduction of febrile but not allergic reactions to RBCs and platelets after conversion to universal prestorage leukoreduction | Q40543308 | ||
| CD40 is constitutively expressed on platelets and provides a novel mechanism for platelet activation. | Q40658295 | ||
| CD40-mediated signaling in B cells. Balancing cell survival, growth, and death. | Q41095361 | ||
| Deep venous thrombosis in medical-surgical critically ill patients: prevalence, incidence, and risk factors | Q43473293 | ||
| Blood transfusion and the two-insult model of post-injury multiple organ failure. | Q43575882 | ||
| Platelet derived CD154 (CD40 ligand) and febrile responses to transfusion | Q43662394 | ||
| Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: a novel target of thiazolidinediones | Q44438462 | ||
| Platelet transfusions during coronary artery bypass graft surgery are associated with serious adverse outcomes | Q44903709 | ||
| Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes | Q45092053 | ||
| Platelet transfusion and survival in adults with acute leukemia | Q45240552 | ||
| Neutrophil CD40 enhances platelet-mediated inflammation | Q46741873 | ||
| The CD40-TRAF6 axis is the key regulator of the CD40/CD40L system in neointima formation and arterial remodeling | Q47245105 | ||
| Platelet products prepared by different methods of sedimentation undergo platelet activation differently during storage. | Q50649227 | ||
| CD154 induces a switch in pro-survival Bcl-2 family members in chronic lymphocytic leukaemia. | Q53531377 | ||
| Oxidative stress-mediated platelet CD40 ligand upregulation in patients with hypercholesterolemia: effect of atorvastatin | Q58421049 | ||
| Cutting Edge: Anti-CD154 Therapeutic Antibodies Induce Infectious Transplantation Tolerance | Q61651670 | ||
| Activated platelets induce tissue factor expression on human umbilical vein endothelial cells by ligation of CD40 | Q62604578 | ||
| CD40L stabilizes arterial thrombi by a β3 integrin–dependent mechanism | Q63354517 | ||
| The effects of blood transfusion on cytokine production by TH1 and TH2 lymphocytes in the mouse | Q71023285 | ||
| Human epidermal keratinocytes are induced to secrete interleukin-6 and co-stimulate T lymphocyte proliferation by a CD40-dependent mechanism | Q71118322 | ||
| Cytokine secretion after allogeneic or autologous blood transfusion | Q72559518 | ||
| CD40 is a functional activation antigen and B7-independent T cell costimulatory molecule on normal human lung fibroblasts | Q73326047 | ||
| Platelet-derived CD40L: the switch-hitting player of cardiovascular disease | Q74627856 | ||
| CD40L induces proliferation, self-renewal, rescue from apoptosis, and production of cytokines by CD40-expressing AML blasts | Q78493565 | ||
| The causes and treatment of reactions to platelet transfusions | Q78859791 | ||
| An association of soluble CD40 ligand (CD154) with adverse reactions to platelet transfusions | Q79142074 | ||
| CD40: Lord of the endothelial cell | Q79696648 | ||
| Release of potential immunomodulatory factors during platelet storage | Q79889339 | ||
| Evidence of Toll-like receptor molecules on human platelets | Q81479217 | ||
| CD40: an upstream master switch for endothelial cell activation uncovered by RNAi-coupled transcriptional profiling | Q81724807 | ||
| Cooperation between platelet-derived CD154 and CD4+ T cells for enhanced germinal center formation | Q81757066 | ||
| Biologically active CD40 ligand is elevated in sickle cell anemia: potential role for platelet-mediated inflammation | Q83118100 | ||
| P433 | issue | 2-3 | |
| P304 | page(s) | 251-260 | |
| P577 | publication date | 2009-01-29 | |
| P1433 | published in | Immunologic Research | Q15754981 |
| P1476 | title | The platelet as an immune cell-CD40 ligand and transfusion immunomodulation | |
| P478 | volume | 45 |
| Q36234916 | A High Level of Soluble CD40L Is Associated with P. aeruginosa Infection in Patients with Cystic Fibrosis |
| Q33618448 | A computerized prediction model of hazardous inflammatory platelet transfusion outcomes |
| Q24198288 | A therapeutic-only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with haematological disorders after chemotherapy or stem cell transplantation |
| Q24186913 | A therapeutic-only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation |
| Q48272685 | Agonist-induced platelet reactivity correlates with bleeding in haemato-oncological patients |
| Q24198795 | Alternative agents versus prophylactic platelet transfusion for preventing bleeding in patients with haematological disorders after chemotherapy or stem cell transplantation |
| Q30248355 | Alternatives, and adjuncts, to prophylactic platelet transfusion for people with haematological malignancies undergoing intensive chemotherapy or stem cell transplantation. |
| Q28083403 | Are Platelets Cells? And if Yes, are They Immune Cells? |
| Q90392210 | Assessment of soluble platelet CD40L and CD62P during the preparation process and the storage of apheresis platelet concentrates: Absence of factors related to donors and donations |
| Q45059688 | Blood platelets and biological response to 'danger' signals and subsequent inflammation: towards a new paradigm? |
| Q24198774 | Comparison of different platelet count thresholds to guide administration of prophylactic platelet transfusion for preventing bleeding in patients with haematological disorders after chemotherapy or stem cell transplantation |
| Q24187751 | Comparison of different platelet count thresholds to guide administration of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation |
| Q24187258 | Comparison of different platelet transfusion thresholds prior to insertion of central lines in patients with thrombocytopenia |
| Q24187460 | Comparison of different platelet transfusion thresholds prior to insertion of central lines in patients with thrombocytopenia |
| Q24198832 | Different doses of prophylactic platelet transfusion for preventing bleeding in patients with haematological disorders after chemotherapy or stem cell transplantation |
| Q24186359 | Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation |
| Q39247582 | Disseminated fusariosis and endogenous fungal endophthalmitis in acute lymphoblastic leukemia following platelet transfusion possibly due to transfusion-related immunomodulation |
| Q36393452 | Evaluation of platelet function during extended storage in additive solution, prepared in a new container that allows manual buffy-coat platelet pooling and leucoreduction in the same system. |
| Q55280563 | Immature platelets and antiplatelet therapy response to aspirin in Kawasaki disease. |
| Q45832206 | Immune-reactive soluble OX40 ligand, soluble CD40 ligand, and interleukin-27 are simultaneously oversecreted in platelet components associated with acute transfusion reactions. |
| Q41961320 | Immunology at the university of Rochester |
| Q33417080 | Impact of platelet transfusion on toxicity and mortality after hematopoietic progenitor cell transplantation |
| Q50532526 | Is the number of blood products transfused associated with lower survival in children with acute lymphoblastic leukemia? |
| Q49443114 | Leucocyte cytokines dominate platelet cytokines overtime in non-leucoreduced platelet components |
| Q50436820 | Leucoreduction helps to preserve activity of antioxidant barrier enzymes in stored red blood cell concentrates. |
| Q33631250 | Moving CLABSI prevention beyond the intensive care unit: risk factors in pediatric oncology patients |
| Q30248755 | Optimal transfusion practices after allogeneic hematopoietic cell transplantation: a systematic scoping review of evidence from randomized controlled trials. |
| Q91971794 | Platelet Inflammatory Response to Stress |
| Q52327633 | Platelet and TRALI: From blood component to organism. |
| Q50797044 | Platelet components associated with adverse reactions: predictive value of mitochondrial DNA relative to biological response modifiers. |
| Q38362628 | Platelet transfusion - the new immunology of an old therapy |
| Q33395509 | Platelet transfusions for patients with haematological malignancies: who needs them? |
| Q34708937 | Platelet transfusions: impact on hemostasis, thrombosis, inflammation and clinical outcomes |
| Q33870639 | Platelet transfusions: trigger, dose, benefits, and risks |
| Q92585772 | Platelet-derived bio-products: Classification update, applications, concerns and new perspectives |
| Q38017397 | Platelets and cytokines: How and why? |
| Q39442668 | Platelets as autonomous drones for hemostatic and immune surveillance |
| Q26739670 | Platelets in Pulmonary Immune Responses and Inflammatory Lung Diseases |
| Q33604443 | Platelets in defense against bacterial pathogens |
| Q84760512 | Platelets--to transfuse or not to transfuse |
| Q35101184 | Platelets: versatile effector cells in hemostasis, inflammation, and the immune continuum |
| Q33415057 | Prospective observational cohort study of the association between thromboelastometry, coagulation and platelet parameters and bleeding in patients with haematological malignancies- the ATHENA study |
| Q102075393 | Similarities and differences between the 'cytokine storms' in acute dengue and COVID-19 |
| Q35558233 | Soluble CD40 ligand, a mediator of sepsis or of transfusion-related adverse effects? |
| Q54941751 | The Non-Hemostatic Aspects of Transfused Platelets. |
| Q41264625 | The association between platelet transfusion and idiopathic pneumonia syndrome is unaffected by platelet product type |
| Q44922653 | The effect of platelet-derived microparticles in stored apheresis platelet concentrates on polymorphonuclear leucocyte respiratory burst |
| Q26863134 | The signaling role of CD40 ligand in platelet biology and in platelet component transfusion |
| Q83762576 | The slippery slope of platelet transfusion for intracerebral hemorrhage |
| Q38725992 | Transfusion-related acute lung injury: transfusion, platelets and biological response modifiers |
| Q48236843 | Use of Aspirin and P2Y12 Response Assays in Detecting Reversal of Platelet Inhibition With Platelet Transfusion in Patients With Traumatic Brain Injury on Antiplatelet Therapy |
Search more.